FDA says manufacturing delays are constraining EpiPen supply
NEW YORK (Reuters) - The U.S. Food and Drug Administration added Mylan NV's EpiPen to its list of drugs in shortage on Wednesday, saying that manufacturing delays were creating intermittent supply constraints of the emergency allergy treatment.
from Reuters: Health News https://reut.rs/2KJ1ATr
http://bit.ly/2zwRqiM